Advertisement

Topics

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

14:11 EDT 13 Jul 2018 | SCRIP

As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a...

      

Related Stories

 

Original Article: Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

NEXT ARTICLE

More From BioPortfolio on "Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...